Barclays raised the firm’s price target on Oruka Therapeutics (ORKA) to $78 from $50 and keeps an Overweight rating on the shares ahead of the ORKA-001 readout. The firm says the stock’s risk/reward is “skewed to the upside” given Oruka’s valuation and the size of the psoriasis market.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics price target raised to $75 from $50 at UBS
- Oruka Therapeutics price target raised to $125 from $60 at Guggenheim
- Oruka Therapeutics files $1B mixed securities shelf
- ORKA-001 Phase 1 Completion: What Oruka’s First-in-Human Milestone Means for Investors
- Oruka Therapeutics price target raised to $86 from $58 at Leerink